AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3405343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (adjuvant chemotherapy with cyclophosphane, methotrexate, 5‐fluorouracil)
Number of subjects: 720
Study 3405343 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 720
Study 31915895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium butyrate (4 g daily for 1 month)
Number of subjects: 30
Study 31915895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31070609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattokinase supplementation
Number of subjects: 50
Study 29284448 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method Intervention (ESM-I) consisting of six weeks of ESM combined with weekly feedback regarding the individual's positive affective experiences
Number of subjects: 101
Study 29284448 — intervention group
Group type: COMPARATOR
Intervention: Experience Sampling Method without feedback
Number of subjects: 101
Study 29284448 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 101
Study 25387855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0
Study 25387855 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 22132711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg intravitreal injections of triamcinolone acetonide (IVTA); 21 patients in the IVTA group
Number of subjects: 43
Study 22132711 — intervention group
Group type: COMPARATOR
Intervention: 1.25-mg intravitreal injections of bevacizumab (IVB); 22 patients in the IVB group
Number of subjects: 43
Study 22132711 — intervention group
Group type: COMPARATOR
Intervention: Control group (IVTA)
Number of subjects: 43
Study 21607794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg by mouth three times a day starting on postoperative day 1
Number of subjects: 30
Study 21607794 — intervention group
Group type: COMPARATOR
Intervention: Minimal amount of water
Number of subjects: 30
Study 18485172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms of self-administered vaginal misoprostol
Number of subjects: 0
Study 18485172 — intervention group
Group type: COMPARATOR
Intervention: Self-administered vaginal placebo
Number of subjects: 0
Study 16170522 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker light provocation
Number of subjects: 28
Study 16170522 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement and flicker light provocation
Number of subjects: 28
Study 16170522 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examinations
Number of subjects: 28
Study 12930165 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g Cr.kg(‐1) body mass for 5 days, followed by 2.25 g Cr for 9 days)
Number of subjects: 15
Study 12930165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10737689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit & Firm (moderate-intensity endurance and strengthening exercises)
Number of subjects: 103
Study 10737689 — intervention group
Group type: COMPARATOR
Intervention: Stretch & Flex (stretching and flexibility exercises)
Number of subjects: 103
Study 9362855 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bath
Number of subjects: 200
Study 9362855 — intervention group
Group type: COMPARATOR
Intervention: Late bath
Number of subjects: 200
Study 1545849 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (36 units per kilogram of body weight three times weekly)
Number of subjects: 20
Study 1545849 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (18 units per kilogram three times weekly)
Number of subjects: 20
Study 1545849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1545849 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 20
Study 1545849 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pruritus
Number of subjects: 20
Study 4037908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube-Placebo
Number of subjects: 200
Study 4037908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube-Cimetidine
Number of subjects: 200
Study 4037908 — intervention group
Group type: COMPARATOR
Intervention: No Tube-Placebo
Number of subjects: 200
Study 4037908 — intervention group
Group type: COMPARATOR
Intervention: No Tube-Cimetidine
Number of subjects: 200
Study 31965179 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Leucine (192 mg/kg body mass) administered daily for 10 weeks
Number of subjects: 24
Study 31965179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leucine supplementation)
Number of subjects: 24
Study 31612956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis co-use
Number of subjects: 157
Study 31612956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol co-use
Number of subjects: 157
Study 31612956 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 157
Study 29887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting (BIKE, n=19)
Number of subjects: 90
Study 29887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of moderate intensity (MOD, n=31)
Number of subjects: 90
Study 29887998 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time exercise of vigorous intensity (VIG, n=24)
Number of subjects: 90
Study 29887998 — intervention group
Group type: COMPARATOR
Intervention: Habitual lifestyle (CON, n=16)
Number of subjects: 90
Study 27563630 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT), one session per week for 4 weeks, using focus probe with varying energy levels (0.05, 0.07, 0.1, and 0.15) and shock numbers (800, 900, 1000, and 1100) from the first to the fourth session.
Number of subjects: 60
Study 27563630 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment including wrist splint at night for 3 months, nonsteroidal anti-inflammatory drugs for 2 weeks, and oral Vitamin B1 for a month.
Number of subjects: 60
Study 25091879 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 683
Study 25091879 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (increased or maintained)
Number of subjects: 683
Study 25091879 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 683
Study 22249153 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil IVPCA
Number of subjects: 39
Study 22249153 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EDA)
Number of subjects: 39
Study 21171756 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional reappraisal
Number of subjects: 0
Study 21171756 — intervention group
Group type: COMPARATOR
Intervention: Expressive suppression
Number of subjects: 0
Study 21171756 — intervention group
Group type: COMPARATOR
Intervention: No-regulation
Number of subjects: 0
Study 17629590 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg MMPD q12h
Number of subjects: 31
Study 17629590 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg MMPD q12h
Number of subjects: 31
Study 17629590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15610942 — intervention group
Group type: EXPERIMENTAL
Intervention: Catatonia group (n=72; 32% of total)
Number of subjects: 225
Study 15610942 — intervention group
Group type: COMPARATOR
Intervention: Noncatatonic group
Number of subjects: 225
Study 11893235 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B 10,000U
Number of subjects: 0
Study 11893235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11893235 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B 2500 to 10,000U
Number of subjects: 0
Study 11893235 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 0
Study 10442065 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine salts
Number of subjects: 10
Study 10442065 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 7608225 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression with laminotomy and medial facetectomy (Group I)
Number of subjects: 45
Study 7608225 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression and arthrodesis of the most stenotic segment (Group II)
Number of subjects: 45
Study 7608225 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression and arthrodesis of all decompressed vertebral segments (Group III)
Number of subjects: 45
Study 7608225 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain relief between Group I and Group II
Number of subjects: 45
Study 7608225 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain relief between Group II and Group III
Number of subjects: 45
Study 7608225 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain relief between Group I and Group III
Number of subjects: 45
Study 2145645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous colchicine
Number of subjects: 0
Study 2145645 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 0
Study 406626 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana extract calibrated to 0.3 mg/kg delta‐9‐tetrahydrocannabinol
Number of subjects: 16
Study 406626 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 16
Study 31097078 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised individual CBT plus TAU (up to 12 sessions delivered within 16 weeks)
Number of subjects: 230
Study 31097078 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 230
Study 31097078 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised individual CBT plus TAU (subgroup analysis for those widowed, divorced or separated)
Number of subjects: 230
Study 31097078 — intervention group
Group type: COMPARATOR
Intervention: TAU (subgroup analysis for those widowed, divorced or separated)
Number of subjects: 230
Study 31097078 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised individual CBT plus TAU
Number of subjects: 230
Study 28108424 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel cervical total disk replacement (MCTDR)
Number of subjects: 24
Study 25736132 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted rectal cancer resection using ENDO RLC general endoscopic linear cutter and single-use loading unit and circular staplers from REACH medical equipment co.LTD
Number of subjects: 64
Study 25736132 — intervention group
Group type: COMPARATOR
Intervention: Surgery with corresponding products widely used (from Johnson and Johnson Medical Equipment C.Ltd)
Number of subjects: 64
Study 23608971 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 90
Study 23608971 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy initiation
Number of subjects: 90
Study 21762269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy for 14 days (pantoprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, bismuth subcitrate 240 mg b.i.d.)
Number of subjects: 417
Study 21762269 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy for 10 days (pantoprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, bismuth subcitrate 240 mg b.i.d.)
Number of subjects: 417
Study 21762269 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy for 14 days
Number of subjects: 417
Study 21762269 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy for 10 days
Number of subjects: 417
Study 19725861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved aortic homograft (CH)
Number of subjects: 28
Study 19725861 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype stentless bioprosthesis (SS)
Number of subjects: 28
Study 19725861 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stented bioprosthesis (SD)
Number of subjects: 28
Study 19725861 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 17767071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 mL/kg
Number of subjects: 40
Study 17767071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 6-8 mL/kg
Number of subjects: 40
Study 17767071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 30 minutes duration at a rate of 15
Number of subjects: 40
Study 15383198 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (median dosage, 200 mg/day)
Number of subjects: 92
Study 15383198 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (median dosage, 3 mg/day)
Number of subjects: 92
Study 11546721 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique (NT) for positioning the LM-DLT by fibreoptic bronchoscopy (FOB)
Number of subjects: 61
Study 11546721 — intervention group
Group type: COMPARATOR
Intervention: Classic technique (CT) for positioning the LM-DLT
Number of subjects: 61
Study 9691901 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo planar imaging (MRI)
Number of subjects: 0
Study 9691901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no in utero echo planar imaging exposure)
Number of subjects: 0
Study 8165628 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g dried ginger
Number of subjects: 8
Study 8165628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2901018 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hypertonic saline infusion of 1200 ml of 2.5% NaCl)
Number of subjects: 8
Study 2901018 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (selective beta-blockade)
Number of subjects: 8
Study 2901018 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blockade)
Number of subjects: 8
Study 31865790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure strategy (systolic blood pressure <120 mm Hg)
Number of subjects: 9361
Study 31865790 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure strategy (systolic blood pressure <140 mm Hg)
Number of subjects: 9361
Study 30009543 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (group A, n=44)
Number of subjects: 84
Study 30009543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, n=40)
Number of subjects: 84
Study 30009543 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (group A)
Number of subjects: 84
Study 30009543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 84
Study 26546403 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg MgSO4 plus 40 mg lidocaine (Group M+L)
Number of subjects: 300
Study 26546403 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine (Group L)
Number of subjects: 300
Study 26546403 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg MgSO4 (Group M)
Number of subjects: 300
Study 24700706 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with TAXUS Express paclitaxel-eluting stents
Number of subjects: 705
Study 24700706 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 705
Study 24700706 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 705
Study 23244706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group
Number of subjects: 69
Study 23244706 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 69
Study 20569719 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) stimulation
Number of subjects: 176
Study 20569719 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular (LV) stimulation
Number of subjects: 176
Study 19046178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N(2)O)
Number of subjects: 50
Study 19046178 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 50
Study 15754197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam prophylaxis (3 g every 6 h for 3 days) plus standard treatment
Number of subjects: 100
Study 15754197 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 100
Study 10334615 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice (two 10- to 15-minute counseling sessions)
Number of subjects: 158
Study 10334615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 158
Study 8564099 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 23
Study 8564099 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 23
Study 8564099 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (PGE1-analogue)
Number of subjects: 23
Study 8564099 — intervention group
Group type: COMPARATOR
Intervention: 2% Ethanol
Number of subjects: 23
Study 1919626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for 2 years)
Number of subjects: 1846
Study 6313029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 3 months and 150 mg at night for 9 months
Number of subjects: 20
Study 6313029 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study 31752517 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 2800
Study 31752517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study 29878650 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion continued for 24 hours postpartum
Number of subjects: 1113
Study 29878650 — intervention group
Group type: COMPARATOR
Intervention: No magnesium sulphate infusion (stopped immediately after delivery)
Number of subjects: 1113
Study 27275843 — intervention group
Group type: EXPERIMENTAL
Intervention: Urocortin 2 (36-360 pmol min(-1))
Number of subjects: 16
Study 27275843 — intervention group
Group type: EXPERIMENTAL
Intervention: Urocortin 3 (1.2-12 nmol min(-1))
Number of subjects: 16
Study 27275843 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol min(-1))
Number of subjects: 16
Study 27275843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (573-5730 pmol kg(-1) min(-1))
Number of subjects: 16
Study 27275843 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 16
Study 25187049 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67
Study 25187049 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR)
Number of subjects: 67
Study 25187049 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) daily practice
Number of subjects: 67
Study 25187049 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 67
Study 22258203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 102
Study 22258203 — intervention group
Group type: EXPERIMENTAL
Intervention: State Entropy (SE)
Number of subjects: 102
Study 22258203 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Discrepancies (DR)
Number of subjects: 102
Study 22258203 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Discrepancies (DR)
Number of subjects: 102
Study 22258203 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 102
Study 22258203 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode Position
Number of subjects: 102
Study 20036147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed SBCC (n = 42)
Number of subjects: 84
Study 20036147 — intervention group
Group type: COMPARATOR
Intervention: Noncuffed SBCC (n = 42)
Number of subjects: 84
Study 20036147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed SBCC
Number of subjects: 84
Study 20036147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Cuffed and Noncuffed SBCCs
Number of subjects: 84
Study 17347862 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sessions of constant low-energy treatment (0.08 mJ/mm(2); 1000 impulses) without local anesthesia
Number of subjects: 50
Study 17347862 — intervention group
Group type: COMPARATOR
Intervention: Two middle-energy treatments (0.2 mJ/mm(2); 2000 impulses) with subacromial anesthesia
Number of subjects: 50
Study 17006287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine alone (dose 1)
Number of subjects: 617
Study 17006287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine alone (dose 2)
Number of subjects: 617
Study 17006287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine concomitantly with other vaccines
Number of subjects: 617
Study 14608267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) and Lactobacillus sporogenes preparation
Number of subjects: 120
Study 14608267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11071838 — intervention group
Group type: EXPERIMENTAL
Intervention: SunSafe multicomponent, community‐based intervention
Number of subjects: 1490
Study 11071838 — intervention group
Group type: COMPARATOR
Intervention: Control towns
Number of subjects: 1490
Study 8930233 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing live Lactobacillus acidophilus (150 mL daily)
Number of subjects: 46
Study 8930233 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized yogurt
Number of subjects: 46
Study 1422689 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 277
Study 1422689 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy alone
Number of subjects: 277
Study 1422689 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (orchiectomy + radiotherapy)
Number of subjects: 277
Study 6334435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (SK)
Number of subjects: 50
Study 6334435 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 50
Study 30709714 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-median intake of vitamin C
Number of subjects: 159
Study 30709714 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-median intake of magnesium
Number of subjects: 159